File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Efficacies of one year nucleos(t)ide analogue therapy in intrahepatic HBV DNA and covalently closed circular DNA reduction

TitleEfficacies of one year nucleos(t)ide analogue therapy in intrahepatic HBV DNA and covalently closed circular DNA reduction
Authors
KeywordsMedical sciences
Gastroenterology
Issue Date2011
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
Citation
The 46th Annual Meeting of the European Association for the Study of the Liver (EASL 2011), Berlin, Germany, 30 March-3 April 2011. In Journal of Hepatology, v. 54 suppl. 1, p. S303, abstract no. 754 How to Cite?
AbstractBACKGROUND AND AIMS: Nucleos(t)ide analogues (NA) are effective in the reduction of HBV viral load. We aimed to investigate their 1 year effects on intrahepatic total HBVDNA and covalently closed circular DNA (cccDNA) levels. METHODS: We recruited from our center 124 patients who had baseline and year 1 liver biopsies and taken part in three phase III international clinical trials (BEHoLD [entecavir vs. lamivudine], GLOBE [telbivudine vs. lamivudine] and QUASH [clevudine vs. adefovir]). These NA were categorized into the more potent group (entecavir, telbivudine, and clevudine; 36 HBeAg-positive and 35 HBeAg-negative patients) and less potent group (lamivudine and adefovir; 31 HBeAg-positive and 22 HBeAg-negative patients). Intrahepatic HBV DNA and cccDNA were measured by real-time PCR. Serum HBV DNA was measured by the COBAS TaqMan HBV Monitor Test. RESULTS: After 1 year of NA therapy, in the HBeAg-positive patients, the more potent NA caused a greater mean reduction of serum HBV DNA than the less potent group (6.7 vs. 5.0 logs, respectively; P = 0.005). In the HBeAg-negative patients, there was no significant difference in serum HBV DNA reduction between the more potent and less potent groups (4.9 vs. 4.7 logs, respectively, P = NS). There were no significant differences between the more potent and less potent groups in the mean reduction of intrahepatic total HBV DNA (2.1 vs. 1.8 logs respectively in HBeAg-positive patients and 1.4 vs. 1.6 logs respectively in HBeAg-negative patients) and cccDNA (1.1 vs. 0.9 logs respectively in both HBeAg-positive and HBeAg-negative patients; all P = NS). Although 88/124 (71%) patients had undetectable serum HBV DNA at year 1, all patients had detectable intrahepatic total HBV DNA. Only five patients (all HBeAg-negative) had undetectable cccDNA after 1 year; nine patients had an increase in cccDNA. CONCLUSIONS: 71% of patients had undetectable serum HBV DNA after 1 year, but intrahepatic total HBV DNA and cccDNA, though reduced, were still detectable in the majority of patients. This suggests that even when highly potent NA are used, a longer term of NA therapy is needed to reduce intrahepatic HBV DNA.
DescriptionThis journal suppl. is Abstract Book of The International Liver Congress™ 2011
Posters
Persistent Identifierhttp://hdl.handle.net/10722/135917
ISSN
2014 Impact Factor: 11.336
2014 SCImago Journal Rankings: 3.477

 

DC FieldValueLanguage
dc.contributor.authorWong, Den_US
dc.contributor.authorLai, CLen_US
dc.contributor.authorSeto, WKen_US
dc.contributor.authorFung, Jen_US
dc.contributor.authorHuang, FYen_US
dc.contributor.authorHung, IFNen_US
dc.contributor.authorYuen, RMFen_US
dc.date.accessioned2011-07-27T01:59:41Z-
dc.date.available2011-07-27T01:59:41Z-
dc.date.issued2011en_US
dc.identifier.citationThe 46th Annual Meeting of the European Association for the Study of the Liver (EASL 2011), Berlin, Germany, 30 March-3 April 2011. In Journal of Hepatology, v. 54 suppl. 1, p. S303, abstract no. 754en_US
dc.identifier.issn0168-8278-
dc.identifier.urihttp://hdl.handle.net/10722/135917-
dc.descriptionThis journal suppl. is Abstract Book of The International Liver Congress™ 2011-
dc.descriptionPosters-
dc.description.abstractBACKGROUND AND AIMS: Nucleos(t)ide analogues (NA) are effective in the reduction of HBV viral load. We aimed to investigate their 1 year effects on intrahepatic total HBVDNA and covalently closed circular DNA (cccDNA) levels. METHODS: We recruited from our center 124 patients who had baseline and year 1 liver biopsies and taken part in three phase III international clinical trials (BEHoLD [entecavir vs. lamivudine], GLOBE [telbivudine vs. lamivudine] and QUASH [clevudine vs. adefovir]). These NA were categorized into the more potent group (entecavir, telbivudine, and clevudine; 36 HBeAg-positive and 35 HBeAg-negative patients) and less potent group (lamivudine and adefovir; 31 HBeAg-positive and 22 HBeAg-negative patients). Intrahepatic HBV DNA and cccDNA were measured by real-time PCR. Serum HBV DNA was measured by the COBAS TaqMan HBV Monitor Test. RESULTS: After 1 year of NA therapy, in the HBeAg-positive patients, the more potent NA caused a greater mean reduction of serum HBV DNA than the less potent group (6.7 vs. 5.0 logs, respectively; P = 0.005). In the HBeAg-negative patients, there was no significant difference in serum HBV DNA reduction between the more potent and less potent groups (4.9 vs. 4.7 logs, respectively, P = NS). There were no significant differences between the more potent and less potent groups in the mean reduction of intrahepatic total HBV DNA (2.1 vs. 1.8 logs respectively in HBeAg-positive patients and 1.4 vs. 1.6 logs respectively in HBeAg-negative patients) and cccDNA (1.1 vs. 0.9 logs respectively in both HBeAg-positive and HBeAg-negative patients; all P = NS). Although 88/124 (71%) patients had undetectable serum HBV DNA at year 1, all patients had detectable intrahepatic total HBV DNA. Only five patients (all HBeAg-negative) had undetectable cccDNA after 1 year; nine patients had an increase in cccDNA. CONCLUSIONS: 71% of patients had undetectable serum HBV DNA after 1 year, but intrahepatic total HBV DNA and cccDNA, though reduced, were still detectable in the majority of patients. This suggests that even when highly potent NA are used, a longer term of NA therapy is needed to reduce intrahepatic HBV DNA.-
dc.languageengen_US
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep-
dc.relation.ispartofJournal of Hepatologyen_US
dc.subjectMedical sciences-
dc.subjectGastroenterology-
dc.titleEfficacies of one year nucleos(t)ide analogue therapy in intrahepatic HBV DNA and covalently closed circular DNA reductionen_US
dc.typeConference_Paperen_US
dc.identifier.emailWong, D: danywong@hku.hken_US
dc.identifier.emailLai, CL: hrmelcl@hku.hken_US
dc.identifier.emailSeto, WK: wkseto@hku.hken_US
dc.identifier.emailFung, J: jfung@hkucc.hku.hken_US
dc.identifier.emailHuang, FY: fungyu@hkucc.hku.hken_US
dc.identifier.emailHung, IFN: ivanhung@hkucc.hku.hken_US
dc.identifier.emailYuen, RMF: mfyuen@hku.hk-
dc.identifier.authorityWong, D=rp00492en_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.identifier.authoritySeto, WK=rp01659en_US
dc.identifier.authorityFung, J=rp00518en_US
dc.identifier.authorityHung, IFN=rp00508en_US
dc.identifier.hkuros188152en_US
dc.identifier.hkuros190367-
dc.identifier.volume54en_US
dc.identifier.issuesuppl. 1-
dc.identifier.spageS303en_US
dc.identifier.epageS303en_US
dc.publisher.placeNetherlands-
dc.description.otherThe 46th Annual Meeting of the European Association for the Study of the Liver (EASL 2011), Berlin, Germany, 30 March-3 April 2011. In Journal of Hepatology, v. 54 suppl. 1, p. S303, abstract no. 754-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats